Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Koba A. Lomashvili"'
Autor:
Steven M. Phillips DO, Stephanie M. Pouch MD, Denise J. Lo MD, Sheetal Kandiah MD, Koba A. Lomashvili MD, Ram A. Subramanian MD, Peter Moran PharmD, Alley Killian PharmD, Prem A. Kandiah MD
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 10 (2022)
Mycoplasma and Ureaplasma infections have been described as a cause of hyperammonemia syndrome leading to devastating neurological injury in the post-transplant period, most commonly in lung transplant recipients. The occurrence of significant hypera
Externí odkaz:
https://doaj.org/article/a4519d6b80b4410aae90618b2f82805c
Autor:
M. Neale Weitzmann, Koba A. Lomashvili, Marc D. McKee, Valentin Nelea, W. Charles O'Neill, Kelly Manning
The extent to which vascular calcification is reversible and the possible mechanisms are unclear. To address this, calcified aortas from uremic mice were transplanted orthotopically into normal mice, and the calcium content, histology, and minerals o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b0e990b34fb14bec17223c741c64fa
https://europepmc.org/articles/PMC5389369/
https://europepmc.org/articles/PMC5389369/
Publikováno v:
Kidney international
Plasma levels of pyrophosphate, an endogenous inhibitor of vascular calcification, are reduced in end-stage renal disease and correlate inversely with arterial calcification. However, it is not known whether the low plasma levels are directly pathoge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6676aacb28b6ccc69574b754732ed602
https://doi.org/10.1038/ki.2013.521
https://doi.org/10.1038/ki.2013.521
Autor:
Marie-Claude Faugere, Hartmut H. Malluche, Bruce L. Riser, W. Charles O'Neill, Koba A. Lomashvili
Publikováno v:
Kidney International. 79:512-517
Pyrophosphate, which may be deficient in advanced renal failure, is a potent inhibitor of vascular calcification. To explore its use as a potential therapeutic, we injected exogenous pyrophosphate subcutaneously or intraperitoneally in normal rats an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47199352f4be14f695b1397071a251f2
https://doi.org/10.1038/ki.2010.461
https://doi.org/10.1038/ki.2010.461
Publikováno v:
Kidney International. 73:1024-1030
Pyrophosphate is a potent inhibitor of medial vascular calcification where its level is controlled by hydrolysis via a tissue-nonspecific alkaline phosphatase (TNAP). We sought to determine if increased TNAP activity could explain the pyrophosphate d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e03460d9fca4229f34733c64c38df3
https://doi.org/10.1038/ki.2008.26
https://doi.org/10.1038/ki.2008.26
Publikováno v:
Journal of the American Society of Nephrology. 16:2495-2500
Pyrophosphate (PPi) is a known inhibitor of hydroxyapatite formation and has been shown to inhibit medial vascular calcification in vitamin D-toxic rats. It was demonstrated recently that endogenous production of PPi prevents calcification of rat aor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef34ec803072793aaadb1659ca756915
https://doi.org/10.1681/asn.2004080694
https://doi.org/10.1681/asn.2004080694
Autor:
Randolph A. Hennigar, W. Charles O'Neill, Kenneth I. Hardcastle, Scott L. Cobbs, Koba A. Lomashvili
Publikováno v:
Journal of the American Society of Nephrology. 15:1392-1401
Hyperphosphatemia is thought to underlie medial vascular calcification in advanced renal failure, but calcification can occur in other conditions in the absence of hyperphosphatemia, indicating that additional factors are important. To identify these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cdc448efe7a4b23c8a29e033154f122
https://doi.org/10.1097/01.asn.0000128955.83129.9c
https://doi.org/10.1097/01.asn.0000128955.83129.9c
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 34(1)
Objective— Calcitriol and various analogs are commonly used to suppress secondary hyperparathyroidism in chronic kidney disease but may also exacerbate vascular calcification. Although this could be because of increased intestinal calcium and phosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05321e969ca76e98729de353c9f9621e
https://pubmed.ncbi.nlm.nih.gov/24202304
https://pubmed.ncbi.nlm.nih.gov/24202304
Matrix Gla protein (MGP) is an inhibitor of vascular calcification but its mechanism of action and pathogenic role are unclear. This was examined in cultured rat aortas and in a model of vascular calcification in rats with renal failure. Both carboxy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9172121f3cb1dc818f73af8532da5710
https://europepmc.org/articles/PMC3190679/
https://europepmc.org/articles/PMC3190679/
Autor:
Alexander M. El-Ali, Erik R. Walp, Stacey Elkhatib, W. Charles O'Neill, Koba A. Lomashvili, Roy L. Sutliff
The contribution of medial calcification to vascular dysfunction in renal failure is unknown. Vascular function was measured ex vivo in control, noncalcified uremic, and calcified uremic aortas from rats with adenine-induced renal failure. Plasma ure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a50d90060606af68a9b8510f34cc238f
https://europepmc.org/articles/PMC3129884/
https://europepmc.org/articles/PMC3129884/